Dental Care Clinics in Woodbury, CT Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Kelly Palchik Dmd, Pc Dentist Medicare: Not Enrolled in Medicare Practice Location: 84 Main St S, Woodbury, CT 06798 Phone: 203-263-2853 Fax: 203-263-2859 |
Family & Preventive Dentistry, Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 357 Main St S, Woodbury, CT 06798 Phone: 203-263-5575 |
Blackwell Dental Pllc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 387 Main St S, Woodbury, CT 06798 Phone: 757-581-9965 |
Lance E. Banwell,dds,pc Dentist Medicare: Not Enrolled in Medicare Practice Location: 387 Main St S, Woodbury, CT 06798 Phone: 203-263-5300 Fax: 203-263-4327 |
James S Bauer Dmd Incorporated Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 40 Main St N Ste E, Woodbury, CT 06798 Phone: 203-263-4402 Fax: 203-263-6211 |
News Archive
New treatment fights respiratory syncytial virus in children
Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).
Enzyme can allow nerve cells in brain to grow and form complex networks: Study
Brain researcher Hiroshi Kawabe has discovered the workings of a process that had been completely overlooked until now, and that allows nerve cells in the brain to grow and form complex networks. The study shows that an enzyme which usually controls the destruction of protein components has an unexpected function in nerve cells: it controls the structure of the cytoskeleton and thus ensures that nerve cells can form the tree-like extensions that are necessary for signal transmission in the brain.
MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF
MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.
Silver nanoparticles may kill beneficial bacteria
Too much of a good thing could be harmful to the environment. For years, scientists have known about silver's ability to kill harmful bacteria and, recently, have used this knowledge to create consumer products containing silver nanoparticles.
FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.
› Verified 9 days ago